HRSV (A) Post-fusion glycoprotein F0, His Tag (MALS verified)

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation.

Product Specifications

Background

Specifications

This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 55.2 kDa. The protein migrates as 47-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Accession Number

P03420

Expression Region

Gln 26 - Leu 513

Host

HEK293

Target

Postfusion glycoprotein F0/post-F protein (RSV)

Conjugation

Unconjugated

Tag

C-10xHis

Source

Human respiratory syncytial virus A (strain A2)

Stability

For long term storage, the product is stable for up to 3 years at -70°C from date of receipt; For short term storage, the product is stable for up to 12 months at 2-8°C from date of receipt. After reconstitution, this product is stable after storage at -70°C for 3 months.

Endotoxin

1.0 EU per μg

Purity

95%

Bioactivity

Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) and HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 μg/mL (100 μL/well) can bind Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) with a linear range of 0.1-4 ng/mL (QC tested).